Skip to content
DataLookout
Start free
Menu

TEADCONCT07563738

A 2-part Phase 1/2 Open-label Trial on ODM-212

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 22 of 23 sites
  2. Eligibility criteria expanded, about 30 words
    • Trial sites expanded: 2 → 23 locations
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Dose Limiting Toxicities and Adverse Events
Timeframe: Through study completion, on average of 2 years

Arms and interventions

ODM-212 with ipilimumab/nivolumab in mesotheliomaExperimental
ODM-212 with gemcitabine and nab-paclitaxel in PDACExperimental
ODM-212 with sotorasib in NSCLCExperimental

Drugs: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib

Sites

23 sites in 7 countries

Spain 6, United States 5, France 4, United Kingdom 3, Denmark 2, Finland 2, Switzerland 1